A large, stylized orange globe graphic with a grid of latitude and longitude lines, positioned in the background of the slide.

# **Accelerating myasthenia gravis diagnosis and treatment: Practical strategies and therapeutic advances**

---

**Practice aid for myasthenia gravis**


For more information, visit: [www.touchNEUROLOGY.com](http://www.touchNEUROLOGY.com)

## When to suspect myasthenia gravis


Most frequent  
presenting symptoms  
include<sup>1,2</sup>

- **Extraocular muscle weakness:** Ptosis, double vision
- **Bulbar muscle weakness:** Difficulty chewing, choking, dysphagia
- **Limb weakness:** Upper limbs usually more impacted than lower limbs

## How to confirm myasthenia gravis diagnosis with serological testing<sup>3</sup>









Treatment algorithm for generalized myasthenia gravis<sup>4</sup>




\*Thymectomy is recommended in AChR+ patients who are eligible and should be performed within 2 years after diagnosis.

Approved advanced therapies for generalized myasthenia gravis<sup>5</sup>

Complement inhibitors	FcRn antagonists
 Eculizumab	  Efgartigimod*
 Ravulizumab	 Rozanolixizumab
 Zilucoplan	

Emerging advanced therapies for generalized myasthenia gravis in phase III trials

Estimated primary completion date



Actual primary completion date



\*A prefilled syringe formulation was approved on 10 April 2025 allowing for administration by patients and/or caregivers.<sup>18</sup>

## Abbreviations and references

### Abbreviations

Ab, antibody; AChR, acetylcholine receptor; C5, C5 component of complement; CBA, cellular assays; ELISA, enzyme-linked immunosorbent assay; FcRn, neonatal Fc receptor; IST, immunosuppressive therapies; IV, intravenous, LRP4, low-density lipoprotein receptor-related protein 4; MG, myasthenia gravis; MuSK, muscle-specific kinase; RIPA, radioimmunoprecipitation assays.

### References

1. Dresser L, et al. *J Clin Med*. 2021;10:2235
2. Beloor Suresh A, Asuncion RMD. Myasthenia Gravis. 2023. In: StatPearls [Internet]. Available at: [www.ncbi.nlm.nih.gov/books/NBK559331/](https://www.ncbi.nlm.nih.gov/books/NBK559331/) (accessed 14 April 2025).
3. Vinciguerra C, et al. *Brain Sci*. 2023;13:1286.
4. De Bleecker JL, et al. *Acta Neurol Belg*. 2024;124:1371–83.
5. Silvestri NJ. *Practical Neurology (US)*. 2024;23:29–32.
6. ClinicalTrials.gov. NCT05716035. Available at <https://clinicaltrials.gov/study/NCT05716035> (accessed 6 May 2025).
7. ClinicalTrials.gov. NCT05403541. Available at: <https://clinicaltrials.gov/study/NCT05403541> (accessed 6 May 2025).
8. ClinicalTrials.gov. NCT05070858. Available at: <https://clinicaltrials.gov/study/NCT05070858> (accessed 28 April 2025).
9. ClinicalTrials.gov. NCT05737160. Available at: <https://clinicaltrials.gov/study/NCT05737160> (accessed 6 May 2025).
10. ClinicalTrials.gov. NCT06744920. Available at: <https://clinicaltrials.gov/study/NCT06744920> (accessed 6 May 2025).
11. ClinicalTrials.gov. NCT06836973. Available at: <https://clinicaltrials.gov/study/NCT06836973> (accessed 6 May 2025).
12. ClinicalTrials.gov. NCT05556096. Available at: <https://clinicaltrials.gov/study/NCT05556096> (accessed 6 May 2025).
13. ClinicalTrials.gov. NCT06456580. Available at: <https://clinicaltrials.gov/study/NCT06456580> (accessed 6 May 2025).
14. ClinicalTrials.gov. NCT06517758. Available at: <https://clinicaltrials.gov/study/NCT06517758> (accessed 6 May 2025).
15. ClinicalTrials.gov. NCT06463587. Available at: <https://clinicaltrials.gov/study/NCT06463587> (accessed 6 May 2025).
16. ClinicalTrials.gov. NCT04951622. Available at: <https://clinicaltrials.gov/study/NCT04951622> (accessed 6 May 2025).
17. ClinicalTrials.gov. NCT04524273. Available at: <https://clinicaltrials.gov/study/NCT04524273> (accessed 6 May 2025).
18. Efgartigimod Prescribing Information. Available at: <https://bit.ly/4dtv71i> (accessed 20 May 2025).

The guidance provided by this practice aid is not intended to directly influence patient care. Clinicians should always evaluate their patients' conditions and potential contraindications and review any relevant manufacturer product information or recommendations of other authorities prior to consideration of procedures, medications or other courses of diagnosis or therapy included here.

Our practice aid coverage does not constitute implied endorsement of any product(s) or use(s). touchNEUROLOGY cannot guarantee the accuracy, adequacy or completeness of any information, and cannot be held responsible for any errors or omissions.